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Abstract
Background: Increasing evidence implicates dysfunctional proteostasis and the involvement of the autophagic and
endo-lysosomal system and the ubiquitin-proteasome system in neurodegenerative diseases. In Alzheimer’s disease
(AD), there is an accumulation of autophagic vacuoles within the neurons. In Parkinson’s disease (PD), susceptibility has
been linked to genes encoding proteins involved in autophagy and lysosomal function, as well as mutations causing
lysosomal disorders. Furthermore, both diseases are characterized by the accumulation of protein aggregates.
Methods: Proteins associated with endocytosis, lysosomal function, and the ubiquitin-proteasome system were identified
in the cerebrospinal fluid (CSF) and targeted by combining solid-phase extraction and parallel reaction monitoring mass
spectrometry. In total, 50 peptides from 18 proteins were quantified in three cross-sectional cohorts including AD (N = 61),
PD (N = 21), prodromal AD (N = 10), stable mild cognitive impairment (N = 15), and controls (N = 68).
Results: A pilot study, including subjects selected based on their AD CSF core biomarker concentrations, showed
increased concentrations of several targeted proteins in subjects with core biomarker levels indicating AD pathology
compared to controls. Next, in a clinically characterized cohort, lower concentrations in CSF of proteins in PD were
found compared to subjects with prodromal AD. Further investigation in an additional clinical study again revealed
lower concentrations in CSF of proteins in PD compared to controls and AD.
Conclusion: In summary, significantly different peptide CSF concentrations were identified from proteins AP2B1, C9,
CTSB, CTSF, GM2A, LAMP1, LAMP2, TCN2, and ubiquitin. Proteins found to have altered concentrations in more than
one study were AP2B1, CTSB, CTSF, GM2A, LAMP2, and ubiquitin. Interestingly, given the genetic implication of
lysosomal function in PD, we did identify the CSF concentrations of CTSB, CTSF, GM2A, and LAMP2 to be altered.
However, we also found differences in proteins associated with endocytosis (AP2B1) and the ubiquitin-proteasome
system (ubiquitin). No difference in any peptide CSF concentration was found in clinically characterized subjects with
AD compared to controls. In conclusion, CSF analyses of subjects with PD suggest a general lysosomal dysfunction,
which resonates well with recent genetic findings, while such changes are minor or absent in AD.
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Introduction
Alzheimer’s disease (AD) [1] and Parkinson’s disease (PD)
[2] are both neurodegenerative diseases characterized by
the accumulation of protein aggregates. In AD, the aggre-
gates are plaques and tangles containing aggregated amyl-
oid β (Aβ) peptide [3] and hyperphosphorylated tau
protein (P-tau) [4–6], respectively. In PD, Lewy bodies are
composed of an aggregated form of α-synuclein protein
[7]. Increasing evidence suggests dysfunctional proteosta-
sis to play a central role in neurodegenerative diseases [8,
9]. Cellular proteostasis is maintained by the degradation
of proteins and organelles by the autophagic and endo-
lysosomal system [10, 11] and the ubiquitin-proteasome
system [12] (see Fig. 1).
In AD, early pathological changes [13] have been identi-
fied by the observations of intraneuronal enlarged early
endosomes [14] and an accumulation of pre-lysosomal au-
tophagic vesicles [15]. Similarly, in PD, an accumulation
of autophagic vacuoles has been seen in patients [16] and
in models of disease [17], accompanied by a decrease in
key player proteins in endo-lysosomal function, such as
LAMP2 [18, 19] and CTSD [20]. Several lines of genetic
evidence indicate the involvement of the autophagic and
endo-lysosomal system in PD [2]. There is a conferred in-
creased risk of developing PD by having mutations in the
GBA gene [21, 22]. Loss of β-glucocerebrosidase, encoded
by the GBA gene, cause Gaucher’s disease, a lysosomal
storage disorder [23]. Recently, genetic variants in numer-
ous lysosomal storage disorder genes were associated with
PD susceptibility [24]. Similarly, genetic variants in nu-
merous genes associated with the autophagic and endo-
lysosomal system, in an aggregated manner, have been in-
dicated to be associated with AD [25]. Indeed, genetic var-
iants in the endocytic genes BIN1 and PICALM have been
associated with the susceptibility of AD [26].
In AD, the core cerebrospinal fluid (CSF) biomarkers
Aβ (specifically the 42 amino acid long variant (Aβ1–42)),
total tau protein (T-tau), and P-tau [27] have been shown
to be potent in discriminating subjects with AD from con-
trols and identify subjects with prodromal AD [28]. Some
studies have also shown altered CSF concentrations in
neurodegenerative diseases of proteins involved in the au-
tophagic and endo-lysosomal system [29–31] and the ubi-
quitin-proteasome system [30, 32–35].
To date, there is no validated biomarker in PD. CSF α-
synuclein concentrations have shown conflicting results,
but often a slight decrease in PD compared to controls
[36], while CSF ubiquitin concentration has been found to
be unaltered [30, 34]. However, lower activity of β-gluco-
cerebrosidase in CSF has been identified [37–39], which is
further decreased in GBA gene mutation carriers [39].
Also, lysosomal membrane proteins have been shown to
exist at lower concentrations in CSF [40]. Collectively,
these findings might indicate dysfunctional lysosomes. A
combination of CSF biomarkers, including the AD CSF
core biomarkers (to exclude amyloid and tau pathology)
and α-synuclein [41, 42], will likely have the highest diag-
nostic value in PD. However, longitudinal studies are
Fig. 1 Cellular systems maintaining proteostasis. Overview of the autophagic and endo-lysosomal system and the ubiquitin-proteasome system.
The proteins investigated in the present paper are shown in association with the parts and regions to which they are functionally associated or
localized. Proteins with peptides found to be significantly altered in any of the three cohorts presented herein have been indicated with a star
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lacking exploring biomarkers showing early alterations
which are necessary for developing effective treatment
strategies.
The aim of the current study was to explore potential
CSF biomarkers associated with the autophagic and
endo-lysosomal system and the ubiquitin-proteasome
system in AD and PD. Identifying biomarkers reflecting
dysfunctional proteostasis in AD [9] and PD [8] could
add valuable information for future developments of
diagnostics and treatments. Herein, an initial explorative
phase was employed to identify and select the proteins
of interest for quantification using solid-phase extraction
(SPE) in combination with parallel reaction monitoring
mass spectrometry (PRM-MS). For the purpose, we
adapted a previously described method [43] holding the
benefits ascribed to PRM-MS; multiplexing capabilities
in complex samples [44, 45]. Using the method, one
pilot cohort and two clinically characterized cohorts
were investigated including subjects with AD (N = 62),
PD (N = 21), prodromal AD (N = 10), stable mild cogni-
tive impairment (MCI; N = 15), and controls (N = 69).
Materials and methods
Participants
Table 1 shows the demographics of the participants in-
cluded in the cross-sectional studies of the present in-
vestigation. Participants designated as subjects having
AD dementia and prodromal AD fulfilled the Inter-
national Working Group biomarker criteria for research
purposes [46] with a concentration of Aβ1–42 < 550 ng/L
in combination with T-tau > 400 ng/L or P-tau phos-
phorylated at Thr181 (P-tau181) > 80 ng/L. One abnor-
mal core biomarker was allowed for control and stable
MCI subjects. No biomarker criteria were applied to
subjects with PD. The pilot study consisted of subjects
with concentrations of the AD CSF core biomarkers sug-
gesting AD pathology (N = 19) or having normal core
biomarker concentrations (controls; N = 24). The bio-
marker profile samples were collected after being ana-
lyzed in clinical routine at the Clinical Neurochemistry
Laboratory, Mölndal, Sweden. In clinical study I, partici-
pants have been consecutively enrolled at the Center of
Memory Disturbances of the University of Perugia. The
cohort included patients affected by AD dementia (N =
6) diagnosed according to the National Institute on
Aging-Alzheimer’s Association criteria [47, 48], patients
diagnosed as PD (N = 10) according to the National In-
stitute of Neurological Disorders and Stroke (NINDS)
diagnostic criteria [49], and subjects diagnosed as MCI
(N = 25) according to Petersen’s criteria [50]. Ten out of
25 developed AD (prodromal AD), while 15 remained
stable for a median of 2 years follow-up (stable MCI).
clinical study II consisted of a set of participants from
the Swedish BioFINDER study [51] recruited at Skåne
University Hospital, Sweden. The study included partici-
pants with AD dementia (N = 36), according to the Na-
tional Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association [52], and participants di-
agnosed with PD (N = 11), according to the NINDS
Table 1 Cohort demographics










Pilot study Control 24 (8/16) 72 (62–74) – 833 (714–998) 42 (36–51) 288 (218–320)
AD 19 (9/10) 76 (71–81)b – 390 (351–456)c 92 (81–104)c 940 (710–1090)c
Clinical study
I
Stable MCI 15 (6/9) 67 (59–76) – 1200 (880–1500) 54 (40–59) 230 (190–320)
Prodromal
AD
10 (7/3) 66 (59–74) – 380 (270–480)d,e 96 (77–160)f,g 690 (510–1100)f,g
AD 6 (2/4) 70 (57–79) – 400 (330–460)d 98 (81–120)g,h 600 (540–860)g,h





75 (68–78) 10/17 890 (660–1100) 45 (38–53) 320 (270–390)
AD 36 (23/
13)
73 (67–77) 25/10 380 (300–440)i,j 74 (65–100)g,i 680 (510–870)g,i
PD 11 (6/5) 69 (68–76) – 660 (430–910) 37 (33–47) 220 (170–320)
aN carriers of one or two APOE ε4 alleles (+) and non-carriers (−)
bP ≤ 0.01, vs control, Wilcoxon 2-sample rank sum test
cP ≤ 0.0001, vs control, Wilcoxon 2-sample rank sum test
dP ≤ 0.001, vs stable MCI, Kruskal-Wallis test with Dunn post hoc
eP ≤ 0.05, vs PD, Kruskal-Wallis test with Dunn post hoc
fP ≤ 0.01, vs stable MCI, Kruskal-Wallis test with Dunn post hoc
gP ≤ 0.001, vs PD, Kruskal-Wallis test with Dunn post hoc
hP ≤ 0.05, vs stable MCI, Kruskal-Wallis test with Dunn post hoc
iP ≤ 0.001, vs control, Kruskal-Wallis test with Dunn post hoc
jP ≤ 0.01, vs PD, Kruskal-Wallis test with Dunn post hoc
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diagnostic criteria [49]. Cognitively healthy volunteers
who underwent cognitive testing and neurologic examin-
ation with no objective cognitive or parkinsonian symp-
toms were included in the control group (N = 44). In
clinical studies I and II, clinical assessment included cog-
nitive testing, psychiatric and neurological assessments
in addition to brain imaging, and collection of CSF and
blood. CSF sampling was performed after informed writ-
ten consent by the patient or the caregiver.
CSF samples
CSF collection was performed as previously described [53,
54]. CSF was collected via lumbar puncture in polypropyl-
ene tubes, centrifuged at room temperature [54] or + 4 °C
[53] for 10min at 2000×g, and aliquoted. Tubes were fro-
zen at − 80 °C pending analysis. CSF Aβ1–42, T-tau, and P-
tau181 concentrations were assessed by using commer-
cially available enzyme-linked immunosorbent assays for
diagnostic purpose (INNOTEST βAmyloid1–42, hTAU-
Ag, and p-TAU181Ag; Fujirebio Europe, Ghent, Belgium),
according to the manufacturer’s instructions.
Sample digestion and SPE
Digestion and SPE were performed as described previ-
ously [43] with minor modifications. In short, 100 μL of
CSF from subject samples or a quality control CSF pool
(QC) was mixed with 25 μL of internal standard mixture
(Additional file 1: Supplementary Methods). Similarly,
100 μL of QC was mixed with 25 μL of six internal stand-
ard mixture reverse calibration curve point dilutions
(Additional file 1: Supplementary Methods). Reduction
and alkylation were performed in three consecutive steps
by (1) the addition of 25 μL 30mM 1,4-dithiothreitol
(Sigma-Aldrich Co., Saint Louis, MO, USA) in 50mM
NH4HCO3 and shaking incubation at + 60 °C for 30min,
(2) incubation for 30min at room temperature, and (3)
addition of 25 μL 70mM iodoacetamide (Sigma-Aldrich
Co.) in 50mM NH4HCO3 and incubation shaking at
room temperature in the dark for 30min. Digestion was
performed by the addition of 25 μL 0.08 μg/μL sequencing
grade modified trypsin (Promega Co., Madison, WI, USA)
in 50mM NH4HCO3 and incubation for 18 h shaking at
+ 37 °C. Digestion was ended by the addition of 25 μL 10%
trifluoroacetic acid. SPE was performed using Oasis HLB
96-well μElution Plates (2mg sorbent and 30 μm particle
size; Waters Co., Milford, MA, USA) and a vacuum mani-
fold station. The wells of the plate were conditioned by
2 × 300 μL methanol and equilibrated with 2 × 300 μL
H2O. The digested samples were loaded followed by a
wash of 2 × 300 μL H2O. Finally, the samples were eluted
in 2 × 100 μL methanol and dried by vacuum centrifuga-
tion. The samples were frozen and stored at − 80 °C pend-
ing analysis.
PRM-MS
The proteins of interest for quantification by PRM-MS
are listed in Table 2. These proteins were identified as
described in Additional file 1: Supplementary Methods.
Digested samples were dissolved in 50 μL 50mM
NH4HCO3 shaking at room temperature for 1 h. Dis-
solved samples were injected (20 μL in half of the pilot
study samples and in clinical study I, and 10 μL in the
other half of the pilot study and in clinical study II) and
separated using a Dionex UltiMate 3000 standard-LC
system (Thermo Fisher Scientific Inc., Waltham, MA,
USA) and a Hypersil GOLD HPLC C18 column (length
200 mm; inner diameter 2.1 mm; particle size 1.9 μm;
Thermo Fisher Scientific Inc.). Mobile phases were as
follow: A: 0.1% formic acid in H2O (v/v) and B: 0.1% for-
mic acid and 84% acetonitrile in H2O (v/v). Separation
was performed at a flow rate of 100 μL/min at + 40 °C
with a gradient going from 2 to 6% B over 2 min, 6 to
20% B over 4 min, and finally 20 to 40% over 42 min.
Micro-flow high-performance liquid chromatography
was performed by online coupling to a hybrid Q Exac-
tive mass spectrometer (Thermo Fisher Scientific Inc.).
Electrospray ionization was performed in positive ion
mode with a HESI-II ionization probe (Thermo Fisher
Scientific Inc.) with the following settings: a spray volt-
age of + 4.1 kV, a heater temperature of + 300 °C, a capil-
lary transfer tube temperature of + 320 °C, a sheath gas
flow rate of 25, and an auxiliary gas flow rate of 10. Ac-
quisition of single microscans was performed in PRM
mode with an isolation window of m/z 3, a resolution
setting of 70 k, an AGC target of 1 × 106, a maximum in-
jection time of 300 ms, and fragmentation with beam-
type collision-induced dissociation (or “higher-energy
collisional dissociation” (HCD) [71]). Targeting of pep-
tides was made within a 2-min acquisition window
where the retention time of the peptides was monitored
in each experimental session using a mixture of stable
isotope-labeled peptides. The peptides targeted and their
mono-isotopic m/z, isolation m/z, and an example of re-
tention time isolation windows are shown in Add-
itional file 2: Table S1. The normalized collision energy,
used for fragmentation with HCD, was optimized for
each peptide by direct infusion of stable isotope-labeled
peptide in solution and varying the energy while moni-
toring the intensity of the product ion in relation to the
precursor ion (Additional file 2: Table S1).
Methodological evaluation
In five separate experiments, eight technical replicate
QC samples were analyzed to determine experimental
precision. Repeatability and intermediate precision were
calculated according to ISO 5725-2 [72]. Additionally
three separate reverse calibration curves were prepared and
analyzed as duplicate technical replicates to investigate
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methodological linearity. The limit of quantification (LOQ)
was set to the concentration range with a relative error ≤
20% of calculated to nominal concentration, determined by
least squares linear regression.
Data analysis
Skyline v3.6 [73] was used for peak detection and peak
area integration. Skyline was set to pick and integrate
[M +H]+ y-ions from a data-independent acquisition
method with a fixed isolation window of m/z 3. Evaluation
of which product ions to include in the integration was
performed by manual inspection of MS/MS spectra,
inspecting individually extracted product ion chromato-
grams in Skyline and by an in-house software comparing
product ion ratios. The evaluation enabled exclusion of
product ions not reproducibly detected and product ions
potentially afflicted by interferences. The ratio of the sum
of the product ion areas of tryptic to isotope-labeled pep-
tide was used for quantification. In the pilot study, the
number of samples, approximately divided by half, was
measured at different occasions. For the pilot study, the
peptide ratio was normalized against the median peptide
ratio of eight QC samples for each respective peptide at
each occasion. The first occasion was normalized against a
factor of 1 (median occasion 1/median occasion 1). The
eight QC of the second occasion were used to normalize
the ratio for each peptide against the first occasion using
multiplication with a factor corresponding to median oc-
casion 1 divided by median occasion 2. The clinical co-
horts were analyzed coherently and thus no normalization
was required.
Statistical analysis
Normality was assessed by evaluating the distribution
using histograms and boxplots as well as by using the
Shapiro-Wilk W test of normality. The non-parametric
Wilcoxon 2-sample rank sum test was used for compar-
ing two groups and the Kruskal-Wallis test with Dunn’s
test for multiple comparisons, comparing all pairs, for
more than two groups. P ≤ 0.05 was considered statisti-
cally significant. Correlations were investigated using
Spearman’s rank correlation where Spearman’s ρ ≥ 0.8 or
≤ − 0.8 and a P value ≤ 0.01 were considered to indicate
a correlation. Statistics were calculated using JMP Pro




AP-2 complex subunit beta P63010 AP2B1 Subunit of the AP2 complex which is central in the formation of clathrin-coated vesicles
in clathrin-mediated endocytosis [55].
Amyloid beta A4 protein P05067 APP Transmembrane protein with a number of suggested functions [56]. Processed by
secretases into fragments, for example Aβ peptides [57].
Complement component C9 P02748 C9 Innate immunity component of the membrane attack complex [58].
Cathepsin B P07858 CTSB Lysosomal cysteine protease with carboxydipeptidase activity [59].
Cathepsin D P07339 CTSD Lysosomal aspartic protease [60].
Cathepsin F Q9UBX1 CTSF Lysosomal cysteine protease [59].
Cathepsin L1 P07711 CTSL Lysosomal cysteine protease [59].
Cathepsin Z Q9UBR2 CTSZ Lysosomal cysteine protease with carboxymonopeptidase activity [59].
Dipeptidyl peptidase 2 Q9UHL4 DPP7 Lysosomal protease producing dipeptides from tripeptides [61].
Ganglioside GM2 activator P17900 GM2A Extracts lipids from membranes. Required for ganglioside GM2 degradation [62].
Beta-hexosaminidase subunit
beta
P07686 HEXB Lysosomal β-hexosaminidase A is a heterodimeric complex composed of Beta-
hexosaminidase subunit beta and subunit alpha [63]. β-hexosaminidase A hydrolyses
ganglioside GM2 with the aid of ganglioside GM2 activator [62].
Lysosome-associated
membrane glycoprotein 1
P11279 LAMP1 Lysosomal transmembrane protein important in vesicle fusion [64], preserving lysosomal
integrity and potentially lysosomal exocytosis [65].
Lysosome-associated
membrane glycoprotein 2
P13473 LAMP2 Lysosomal transmembrane protein important in vesicle fusion [64], chaperone-mediated
autophagy and preserving lysosomal integrity [65].
Lysozyme C P61626 LYZ Glycan cleaving polypeptide. Produced and found in secretory vesicles of neutrophils,
monocytes, macrophages and epithelial cells [66].
Tissue alpha-L-fucosidase P04066 FUCA1 Lysosomal fucosidase hydrolyzing fucose containing glycoconjugates [67].
Transcobalamin-2 P20062 TCN2 Delivers cobalamin to lysosomes where it is released [68].
Tripeptidyl-peptidase 1 O14773 TPP1 Lysosomal aspartic or serine protease producing tripeptides [69].
Ubiquitin P0CG48 Ubiquitina Labels proteins for degradation by the proteasome [12]. Has a multitude of functions as a
post-translational modification [70].
aUbiquitin originate from several genes and is therefore simply referred to as ubiquitin
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v.13.2.1 (SAS Institute Inc., Cary, NC, USA), and graphs
were created using GraphPad Prism v.8.2.0 (GraphPad
Software, Inc., La Jolla, CA, USA). Calibration curves
were created using least square linear regression and
evaluated in GraphPad Prism (GraphPad Software, Inc.).
Results
Identification of target proteins and peptides
Initial exploration was performed to identify proteins of
relevance to include in the panel. First three technical
replicates, dissolved in 0.1% formic acid prior to injec-
tion, and then three technical replicates dissolved in
0.1% formic acid, 50 mM NH4HCO3, or 20% acetonitrile
were analyzed. The proteins identified in steps 1 and 2
are shown in Additional file 3: Table S2. Proteotypic
stable isotope-labeled peptides were acquired for method
development. Ubiquitin in CSF was targeted in a previ-
ous study [35], and now two proteotypic ubiquitin pep-
tides were selected for quantification. In total, 51
peptides from 19 proteins were included in the method,
including added bovine serum albumin as a tool to
monitor the status and variability of the method within
and between experiments.
LOQ and methodological precision
The LOQ was investigated for all peptides by creating a
six-point reversed calibration curve by using least
squares linear regression and was determined as the
concentration range with a relative error of ≤ 20% of cal-
culated to nominal concentration. By analyzing eight
technical replicate QC samples at five separate time
points, the repeatability and intermediate precision of
the peptides were found to range between 3 and 22%
and 7 and 38%, respectively. Three peptides, DPP7
(40–47), LAMP2 (153–161), and FUCA1 (114–130),
were measured outside the LOQ; however, they dis-
played a precision in line with the precision of peptides
measured within the LOQ. The peptide LOQs are
shown in Additional file 2: Table S1 and Additional file 4:
Figure S1. Information about approximate peptide con-
centrations in CSF and precision data are shown in Add-
itional file 2: Table S1. Additionally, extracted ion
chromatograms and MS/MS spectra for all peptides
included in the method are shown in Additional file 5:
Figure S2.
CSF protein concentrations in the pilot study
The pilot study, consisting of subjects having normal CSF
concentrations of the AD CSF core biomarkers or concen-
trations suggesting AD pathology, was analyzed (control,
N = 24; AD, N = 19). The CSF concentration of AP2B1,
CTSB, GM2A, LAMP2, and ubiquitin was significantly in-
creased in the AD group compared to that in the controls
(see Fig. 2 and Table 3). All peptide measurements are
presented in Additional file 6: Table S3. Furthermore, ana-
lyzing correlations in the pilot study, P-tau181 was found
to correlate with one of the AP2B1 peptides (712–719) in
the control group (see Additional file 7: Table S4). No fur-
ther correlations were found between the AD CSF core
biomarkers and the peptides measured, neither in the AD
nor control group. Typically, but not for all peptides, there
was a correlation between peptides originating from the
same protein. Age was found to be significantly different
between AD and controls (Table 1); however, there was
no correlation between age and any of the peptides mea-
sured (Additional file 7: Table S4).
CSF protein concentrations in clinical cohorts
In clinical study I, the investigation continued with mea-
surements of CSF protein concentrations in CSF col-
lected from subjects with prodromal AD (N = 10), stable
MCI (N = 15), AD dementia (N = 6), and PD (N = 10).
The level of several proteins was found to be signifi-
cantly decreased in PD compared to prodromal AD (see
Fig. 3 and Table 3). These included AP2B1, CTSF,
LAMP1, LAMP2, and ubiquitin. No correlation was
found between the AD CSF core biomarkers or age and
the peptide concentrations in the stable MCI group (see
Additional file 7: Table S4 for all correlation informa-
tion). In the prodromal AD group, P-tau181 correlated
with two AP2B1 peptides (712–719 and 835–842) and a
LAMP2 peptide (153–161), and a correlation was also
found between GM2A (89–96) and age. In the AD
group, P-tau181 correlated with one APP peptide (289–
301) and Aβ1–42 correlated with one C9 peptide (146–
154). In the PD group, P-tau181 correlated with all
AP2B1 peptides, one LAMP2 peptide (153–161), and all
ubiquitin peptides. Also, in the PD group, Aβ1–42 corre-
lated with a FUCA1 peptide (163–173).
The finding in clinical study I that proteins had lower
concentration in PD and no alterations in prodromal AD
or AD dementia called for an additional investigation in a
clinical cohort. Clinical study II consisted of subjects with
AD dementia (N = 36), PD (N = 11), and cognitively nor-
mal healthy controls (N = 44). In clinical study II, the con-
centrations of AP2B1, CTSF, GM2A, and ubiquitin were
significantly decreased in PD compared to AD and con-
trols (Fig. 4 and Table 3). Also, C9, CTSB, CTSF, TCN2,
and ubiquitin were found to be significantly decreased in
PD compared to AD. All peptides with significantly differ-
ent CSF concentrations in clinical studies I and II have
been combined showing the results of both studies in
Additional file 8: Figure S3. In clinical study II, correla-
tions were identified between the AD CSF core bio-
markers T-tau and P-tau181 and the AP2B1 and ubiquitin
peptides in the control group (Additional file 7: Table S4).
Moreover, both AP2B1 peptides, one LAMP2 peptide
(281–289), and one ubiquitin peptide (12–27) correlated
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with P-tau181 in the AD group. Finally, both AP2B1 pep-
tides, two LAMP2 peptides (133–144 and 153–161), and
one ubiquitin peptide (12–27) correlated with P-tau181 in
the PD group. A subset of subjects in clinical study II had
a known APOE genotype. Being APOE ε4 positive by
having one or two ε4 alleles had a significant effect on the
CSF protein concentrations in the control group. The level
of C9, CTSF, DPP7, and GM2A was decreased in controls
being APOE ε4-positive carriers (N = 10) compared to
non-carriers (N = 17) (see Additional file 9: Figure S4).
Fig. 2 CSF endo-lysosomal proteins and ubiquitin concentrations in the pilot study. The pilot study included subjects designated as controls (N =
24) or AD (N = 19) based on their CSF AD core biomarker profile. Shown are peptides found to be significantly increased in AD compared to
controls; a AP2B1_712–719 (P < 0.001), b AP2B1_835–842 (P < 0.0001), c AP2B1_868–878 (P < 0.001; peptide measured in: AD, N = 7, and control,
N = 10), d CTSB_80–87 (P < 0.01), e CTSB_210–220 (P < 0.01), f GM2A_89–96 (P < 0.01), g GM2A_170–179 (P < 0.01), h LAMP2_133–144 (P < 0.01), i
LAMP2_281–289 (P < 0.01), j Ubiquitin_12–27 (P < 0.01), and k Ubiquitin_64–72 (P < 0.05). Statistics were calculated using Wilcoxon 2-sample rank
sum test and the graphs show Tukey boxplots
Table 3 Proteins and peptides showing significant differences
Cohort Change Protein (significant peptidesa/peptides measured)
Pilot study ↑AD vs control AP2B1 (3/3)b, CTSB (2/3), GM2A (2/2), LAMP2 (2/4), and ubiquitin (2/2)
Clinical study I ↓PD vs prodromal AD AP2B1 (1/3)b, CTSF (1/4), LAMP1 (1/3), LAMP2 (3/4), and ubiquitin (2/2)
Clinical study II ↓PD vs control AP2B1 (2/2)b, CTSF (2/4), and ubiquitin (1/2)
↓PD vs AD AP2B1 (2/2)b, C9 (1/5), CTSB (1/3), CTSF (4/4), GM2A (2/2), TCN2 (2/3), and ubiquitin (2/2)
aP value of ≤ 0.05 using Wilcoxon 2-sample rank sum test or Kruskal-Wallis test with Dunn post hoc
bThree peptides were measured in a subset of subjects in the pilot study and all subjects in clinical study I. Two peptides were measured in the rest of the pilot
study subjects and clinical study II
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There was no association between APOE ε4 and CSF
protein concentrations in AD (carriers, N = 25; non-
carriers, N = 10).
Discussion
In the present study, an explorative approach has been
used to investigate the CSF concentrations of proteins
associated with endocytosis, lysosomal function, and the
ubiquitin-proteasome system in AD and PD (see Fig. 1).
A method quantifying 18 proteins by measuring 50 pep-
tides, using 100 μL CSF, has been developed. The LOQ
and precision have been described for each peptide. Ini-
tially, the pilot study, including subjects having an AD
CSF core biomarker profile or a normal profile (con-
trols), showed increased CSF concentrations of several
proteins, AP2B1, CTSB, GM2A, LAMP2, and ubiquitin,
in AD compared to controls. Exploration of a clinically
characterized cohort, clinical study I, instead showed
Fig. 3 CSF endo-lysosomal proteins and ubiquitin concentrations in clinical study I. Clinical study I included cross-sectional samples from clinically
characterized subjects with AD (N = 6) and PD (N = 10) as well as longitudinal samples from subjects with prodromal AD (N = 10) and stable MCI
(N = 15). A significant decreased concentration of a AP2B1_868–878 (P < 0.05), b CTSF_103–116 (P < 0.05), c LAMP1_357–363 (P < 0.05), d
LAMP2_133–144 (P < 0.05), e LAMP2_153–161 (P < 0.05), f LAMP2_281–289 (P < 0.01), g Ubiquitin_12–27 (P < 0.05), and h Ubiquitin_64–72 (P <
0.05) was identified in PD compared to prodromal AD. Statistics were calculated using Kruskal-Wallis test with Dunn’s test for multiple
comparisons and the graphs show Tukey boxplots
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Fig. 4 (See legend on next page.)
Sjödin et al. Alzheimer's Research & Therapy           (2019) 11:82 Page 9 of 16
decreased CSF concentrations of AP2B1, CTSB, CTSF,
LAMP1, LAMP2, and ubiquitin in PD compared to pro-
dromal AD. A recent study, using a similar method as
described herein, showed increased CSF concentrations
of proteins involved in vesicular transport and synaptic
function in prodromal AD compared to AD and controls
[74]. Presently, further investigation in an additional
clinically characterized cross-sectional cohort confirmed
decreased CSF concentrations of several proteins in PD
compared to AD and controls, including AP2B1, C9,
CTSB, CTSF, GM2A, TCN2, and ubiquitin. Proteins re-
peatedly identified at altered CSF concentrations, in
more than one of the four studies, were AP2B1, CTSB,
CTSF, GM2A, LAMP2, and ubiquitin, which position
them as the most potent markers of those investigated.
The importance of lysosomal function in PD has been in-
dicated by an increased risk of developing the disease in
carriers of GBA gene mutations [21, 22] and increased sus-
ceptibility having genetic variants in genes associated with
lysosomal storage disorders [24]. β-glucocerebrosidase has
been shown at decreased amounts [75] and activities [75,
76] in the substantia nigra of GBA gene mutation carriers
and non-carriers. Lysosomal alterations in PD seem also to
be measurable in CSF as shown by decreased activities of
β-glucocerebrosidase in PD compared to controls [37–39].
However, unaltered β-glucocerebrosidase activity has also
been indicated [77]. Additionally lower activities have been
shown in dementia with Lewy bodies [78].
We measured primarily lysosomal proteins and did
identify decreased CSF concentrations of several in PD.
We found decreased concentrations of AP2B1, essential
in clathrin-mediated endocytosis [55], in PD compared
to prodromal AD, AD, and controls. To our knowledge,
AP2B1 has not been previously investigated in CSF from
subjects with AD or PD. Further, concentrations of
CTSB and CTSF peptides were also decreased in PD
compared to controls, prodromal AD, and AD dementia.
The cathepsin peptides selected originated from the pro-
peptide, propeptide-active chain cleavage site, and the
active chains to provide functional information. How-
ever, no such information could be deduced from the
present findings. No alterations of CSF concentrations of
CTSD, CTSL, or CTSZ were found in PD. Previous in-
vestigations have revealed decreased [39] or unchanged
[77] CTSD enzymatic activity in CSF in PD compared to
controls. GM2A concentration, which in cooperation
with β-hexosaminidase degrades ganglioside GM2 [62],
was decreased in PD compared to AD and controls in
clinical study II. Previously, the CSF concentration has
been found increased in dementia with Lewy bodies but
unaltered in PD compared to controls [30]. The LAMP1
and LAMP2 concentrations were decreased in PD com-
pared to prodromal AD in clinical study I. Chu et al.
[20] showed decreased levels of LAMP1 in α-synuclein
containing neurons in the substantia nigra of subjects af-
fected by PD. Furthermore, unaltered [30] or decreased
[40] LAMP1 CSF concentrations have been indicated in
PD compared to controls. Three isoforms of LAMP2 ex-
ists: A, B, and C [79]. The peptides measured in the
present study are not isoform specific. LAMP2A is fun-
damental in chaperone-mediated autophagy (CMA) [80],
in which it confers a rate-limiting component [81, 82].
Interestingly, CMA decreases with aging [82] and has
been shown to be involved in the degradation of α-synu-
clein [83, 84]. Murphy et al. showed that the level of
LAMP2A decreased and related to accumulating
amounts of α-synuclein in early PD [19]. Also, the level
of LAMP2A in substantia nigra pars compacta and
amygdala has been shown to be decreased in PD [18].
The CSF concentration of LAMP2 has previously been
indicated to be decreased in PD [40]. The CSF ubiquitin
concentration in PD has been suggested to be un-
changed [30, 34, 85]. However, in the present investiga-
tion, we identified a decreased concentration of ubiquitin
in PD compared to prodromal AD, AD dementia, and
controls. Previously, we found no significant difference in
the CSF concentration of full-length ubiquitin in PD com-
pared to controls or progressive supranuclear palsy [35].
Ubiquitin has been shown to be a component of Lewy
bodies [86, 87]. How this would contribute to lower ubi-
quitin concentration in PD remains speculative. We found
no differences in the CSF concentration of HEXB between
groups. Previously, the CSF enzymatic activity of β-hexos-
aminidase has been shown to be either increased [38], un-
changed [37, 77], or reduced [39] in PD compared to
controls. We also identified significantly decreased con-
centration of TCN2 in PD compared to AD in clinical
study II. TCN2 transports cobalamin to the lysosome,
(See figure on previous page.)
Fig. 4 CSF endo-lysosomal proteins and ubiquitin concentrations in clinical study II. Clinical study II included cross-sectional samples from
clinically characterized subjects with AD (N = 36) and PD (N = 11) as well as cognitively normal healthy controls (N = 44). A significant decreased
concentration of a AP2B1_712–719 (P < 0.001), b AP2B1_835–842 (P < 0.001), c C9_232–242 (P < 0.05), d CTSB_80–87 (P < 0.05), e CTSF_103–116
(P = 0.001), f CTSF_236–245 (P < 0.01), g CTSF_266–278 (P < 0.01), h CTSF_442–450 (P < 0.01), i GM2A_89–96 (P < 0.0001), j GM2A_170–179 (P <
0.0001), k TCN2_45–59 (P < 0.05), l TCN2_300–313 (P < 0.05), m Ubiquitin_12–27 (P < 0.001), and n Ubiquitin_64–72 (P < 0.001) was found in PD
compared to AD. Additionally, a significant decreased concentration of a AP2B1_712–719 (P < 0.01), b AP2B1_835–842 (P < 0.05), e CTSF_103–116
(P < 0.05), h CTSF_442–450 (P < 0.05), i GM2A_89–96 (P < 0.0001), j GM2A_170–179 (P < 0.001), and n Ubiquitin_64–72 (P < 0.05) was identified in
PD compared to controls. Statistics were calculated using Kruskal-Wallis test with Dunn’s test for multiple comparisons and the graphs show
Tukey boxplots
Sjödin et al. Alzheimer's Research & Therapy           (2019) 11:82 Page 10 of 16
where it is released [68]. Disturbed lysosomal acidification
and protease inhibition [88] seem to increase lysosomal
cobalamin retention. Lysosomal dysfunction might thus
cause retention of cobalamin as well as TCN2. C9 is a
component of the innate immunity membrane attack
complex [58]. We observed a significantly lower concen-
tration of C9 (232–242) in PD compared to AD in clinical
study II. C9 expression in the brain has been shown to be
higher in AD compared to controls [89, 90].
In AD, there is an accumulation of intraneuronal en-
larged early endosomes [14] and pre-lysosomal autopha-
gic vesicles [15]. These alterations are accompanied by
an increased expression and presence of endosomal and
lysosomal proteins [91–94]. Additionally, endosomal,
lysosomal, and autophagic proteins have shown elevated
CSF concentrations in AD compared to controls [29].
We did not observe significant differences for any pep-
tides in AD or prodromal AD compared to stable MCI
in clinical study I or between AD dementia and controls
in clinical study II. The pilot study consisted of bio-
chemically characterized subjects suggesting AD path-
ology in the AD group. The subjects could have AD
dementia, prodromal AD, or preclinical AD, alone or in
combination with other comorbidities. Similarly, the
pilot study controls are not necessarily healthy as they
have sought medical advice with a neurological implica-
tion. This might in part explain the discrepancies in the
results between the pilot study and the clinical studies.
Nonetheless, we found elevated concentrations of
AP2B1 in AD compared to non-AD controls in the pilot
study. Musunuri et al. [95] have previously found de-
creased subunit α-1 AP2 levels in the temporal neocor-
tex in AD compared to controls. Also, the CTSB CSF
concentration was increased in AD compared to non-
AD controls in the pilot study. Enzymatically active
CTSB and CTSD have been identified as components of
plaques [96] and shown to have increased cortical and
hippocampal immunoreactivity in AD [91]. Increased
CTSB plasma concentration has previously been shown
in AD [97]. However, the CSF concentration in AD has
been suggested to be unaltered [29, 97] whereas the pro-
enzyme form of CTSL has exhibited increased CSF con-
centration in AD compared to controls [29]. However,
we did not detect any significant differences for any of
the CTSL peptides. Significantly increased concentra-
tions of LAMP2 peptides were observed for AD com-
pared to non-AD controls in the pilot study. Previous
investigations have suggested increased CSF concentra-
tions of LAMP2 [29, 31] as well as LAMP1 [29, 30] in
AD. Recently, GM2A was found to have significantly in-
creased CSF concentration in AD compared to controls
[30]. We here show increased concentrations of GM2A
peptides in AD compared to non-AD controls in the pilot
study. The CSF concentration of ubiquitin has been shown
to be increased in AD [30, 32–35], Creutzfeldt-Jakob dis-
ease [34, 98, 99], and dementia with Lewy bodies [30] com-
pared to controls. Also, the CSF ubiquitin concentration in
prodromal AD has been shown to be higher compared to
subjects with stable MCI [100]. Herein, the CSF concentra-
tion of ubiquitin peptides was found increased in AD com-
pared to non-AD controls in the pilot study. Previously, we
have measured full-length ubiquitin [35]; however, the pep-
tides measured in the current analysis could additionally
originate from post-translationally modified substrates or
polyubiquitin chains.
The CSF concentrations for APP, DPP7, LYZ, FUCA1,
and TPP1 were not significantly altered. When recently
measured, no difference in APP peptide concentration
was found between AD and controls [43]. Furthermore,
a recent meta-analysis showed no difference between the
CSF levels of soluble α- and β-APP in AD compared to
controls [28]. The activity of DPP7 in CSF and serum
has been suggested to be increased in PD [101]. How-
ever, the frontal cortex DPP7 activity in PD and demen-
tia with Lewy bodies has been indicated to be low
compared to controls whereas no difference was de-
tected in AD [102]. Concordant with our recent findings
[43], no alterations in LYZ peptides was identified be-
tween AD and controls. The CSF concentration of LYZ
has previously been suggested to be increased in AD
compared to controls [103, 104]. To our knowledge, the
CSF level of FUCA1 in AD or PD has not previously
been investigated. FUCA1 is a lysosomal glycosidase
[67], and mutations in FUCA1 cause the lysosomal stor-
age disorder fucosidosis [105].
ApoE is a lipid transporter of which three isoforms ex-
ists: E2, E3, and E4 (encoded by the ε2, ε3, and ε4 alleles,
respectively, of the APOE gene) [106]. In a gene dose-
dependent manner, the APOE ε4 allele is the most
prominent genetic risk factor for AD susceptibility [107].
Previously, it has been shown that enlarged endosomes,
as seen early on in AD, are accentuated and even larger
in carriers of APOE ε4 [13]. Furthermore, apoE regulate
Aβ production [108] which is amplified by the E4 iso-
form [108] and apoE4, in conjunction with Aβ, cause
lysosomal leakage [109]. In this paper, we investigated
an association between CSF protein levels and APOE ε4
carrier status and found significant differences between
carriers and non-carriers in cognitively healthy controls.
The protein concentrations of C9, CTSF, DPP7, and
GM2A were decreased in the APOE ε4 carriers. No dif-
ference in protein expression was identified between ε4
carriers and non-carriers with AD; the differences were
confined to the non-AD groups, a finding that needs to
be confirmed in additional studies because of the rela-
tively small sample size. As the increased risk of sporadic
AD having an APOE ε4 genotype also relates to an earl-
ier age of onset [107] additional investigation in a
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longitudinal cohort including subjects with prodromal
AD would be preferable.
The present exploration includes the analysis of a large
number of analytes in a restricted number of partici-
pants which might increase the risk of identifying false
positives. However, four independent cohorts were ana-
lyzed resulting in the identification of a few repeatedly
altered CSF protein concentrations. Not all protein con-
centrations were altered suggesting no general alteration
in protein concentrations in any of the disorders. For
proteins with altered concentrations between groups, in
most cases, not all peptides originating from that protein
had altered concentrations. There are several possible
explanations for this discrepancy, for example, peptides
belonging to different protein domains, endogenous pro-
tein fragments [110], or peptides being subjected to
post-translational modifications. Also, no protein in the
current investigation was specifically of neuronal origin.
The limited number of participants likely also affects
the interpretation of the correlation analyses. For tryptic
peptides originating from the same protein, correlations
were typically high (Additional file 7: Table S4). A
GM2A peptide (89–96) correlated with age in clinical
study 1; however, for this peptide, there was no signifi-
cant difference in concentration between groups. For the
proteins identified at significantly altered levels between
groups; AP2B1, LAMP2, and ubiquitin peptides corre-
lated with P-tau. Ubiquitin is a component of tangles
[86, 111, 112] and CSF P-tau does correlate with the
amount of tangles in the brain [113]. How AP2B1 and
LAMP2 relate to tangle formation remains elusive. We
also found AP2B1 and ubiquitin to correlate with T-tau.
The CSF concentration of T-tau is considered to reflect
neuronal and axonal degeneration [114], a degeneration
which might also explain a leakage of AP2B1 and ubi-
quitin. While T-tau and P-tau were found to correlate
with AP2B1, LAMP2, and ubiquitin which might relate
to the differences observed between prodromal AD and
AD compared to controls and PD, the association with
tau pathology is less clear for the non-correlating pro-
teins CTSB, CTSF, and GM2A. Also, the association
with tau pathology does not explain the differences ob-
served between controls and PD (Fig. 4), for which there
was no difference in the CSF concentration of T-tau and
P-tau181 (Table 1). In PD, lower levels of lysosomal pro-
teins in regions with α-synuclein pathology [18–20]
might in part explain decreased concentrations in CSF.
A pathway for intracellular endo-lysosomal proteins to
reach the CSF might be facilitated by lysosomal exocyt-
osis [115], exosomes [116], and degenerating and dying
neurons. Lysosomal exocytosis [115] serves a purpose in
membrane repair [117], myelination [118], and neurite
outgrowth [119]. Lysosomal exocytosis [117] and neurite
outgrowth [119] might act as a repair response in
damaged neurons. By lysosomal exocytosis, through fu-
sion with the plasma membrane, lysosomal hydrolases
and contents are expelled into the extracellular milieu
[115]. In the CSF, there are a great number of proteins
[120, 121] and endogenous peptides [110]. Considering a
fairly rigid and controlled path of CSF production at the
main site, the choroid plexus [122], it might seem odd to
find these proteins in the CSF. An additional source of
CSF production is the drainage of parenchymal intersti-
tial fluid into the CSF through interstitial fluid bulk flow
[122, 123], a pathway that is however thought to be a
slow process for diffusion of larger molecules [122, 123].
Additional pathways for soluble proteins in the brain
parenchyma to reach the CSF might still be discovered.
Extracellular vesicles in CSF, including exosomes, have
been shown to be associated with several proteins inves-
tigated herein: APP, C9, CTSB, CTSD, CTSF, CTSL,
GM2A, LYZ, TCN2, and ubiquitin [124]. Recently, neu-
ronally derived exosomes in blood were found to contain
elevated concentrations of CTSD, LAMP1, and ubiquiti-
nated proteins already at a preclinical stage of AD, com-
pared to controls and subjects with frontotemporal lobar
degeneration [125].
Conclusion
The present investigation revealed altered CSF concen-
trations of several proteins associated with the endo-
lysosomal system and the ubiquitin-proteasome system
in PD. Potentially, these altered concentrations reflect
dysfunctional proteostasis, which has been suggested to
be a pathological feature of PD [8]. Future studies are re-
quired to examine the biomarker evolvement during PD
onset and progression, as well as how they relate to
genetics. From a biomarker perspective, the involvement
of lysosomal dysfunction in AD pathogenesis appears
limited, at least as compared to PD.
Additional files
Additional file 1: Supplementary Methods. (PDF 157 kb)
Additional file 2: Table S1. Proteins and peptides targeted using a
combination of SPE and PRM-MS. (XLS 55 kb)
Additional file 3: Table S2. Proteins identified in CSF using tandem
mass spectrometry. (XLS 2418 kb)
Additional file 4: Figure S1. Limit of quantification. (PDF 246 kb)
Additional file 5: Figure S2. Extracted ion chromatograms and MS/MS
spectra. (PDF 4086 kb)
Additional file 6: Table S3. Demographics and biomarker data. (XLS
259 kb)
Additional file 7: Table S4. Spearman’s correlation analysis. (XLS 1583
kb)
Additional file 8: Figure S3. Significant peptides in clinical studies I and
II. (PDF 218 kb)
Additional file 9: Figure S4. CSF protein concentrations in APOE ε4
carriers. (PDF 193 kb)
Sjödin et al. Alzheimer's Research & Therapy           (2019) 11:82 Page 12 of 16
Abbreviations
Aβ: Amyloid β peptide; Aβ1–42: 42 amino acid long amyloid β peptide;
AD: Alzheimer’s disease; CSF: Cerebrospinal fluid; HCD: Higher-energy
collisional dissociation; LOQ: Limit of quantification; MCI: Mild cognitive
impairment; MS/MS: Tandem mass spectrometry; NINDS: National Institute of
Neurological Disorders and Stroke; PD: Parkinson’s disease; PRM-MS: Parallel
reaction monitoring mass spectrometry; P-tau: Hyperphosphorylated tau
protein; P-tau181: Tau protein phosphorylated at Thr181; SPE: Solid-phase




AB, KB, OH, LP, SP, SS, and HZ made contributions to the conception and
design of the study. SS performed the experiments. All authors (AB, GB, KB, JH,
OH, LP, SP, SS, HZ, and AÖ) were involved in the analysis and interpretation of
the data. SS drafted the manuscript. All authors have critically revised the
manuscript for intellectual content and read and approved the final manuscript
for submission.
Funding
Funding sources supporting the work presented herein are as follows: AB,
Eivind and Elsa K:Son Sylvans Foundation; AB, the Märtha and Gustaf Ågrens
Foundation; KB and OH, the Swedish Brain Foundation; KB, the Torsten
Söderberg Foundation; KB and OH, the Swedish Alzheimer foundation; AB, GB,
KB and SS, the Foundation for Gamla Tjänarinnor; KB, OH and HZ, the Swedish
Research Council (KB, #20112-2288; HZ, #2013-2546); OH, the Parkinson
foundation of Sweden; SS, Demensfonden; GB, Åhlén Foundation; GB and SS,
the Gun and Bertil Stohnes Foundation; SS, the Wilhelm and Martina Lundgrens
Science Foundation; OH and HZ, the European Research Council (#681712); HZ,
Frimurarestiftelsen; HZ, the Knut and Alice Wallenberg Foundation (#KAW
2013.0180); and an anonymous donor.
Availability of data and materials
The data that support the findings of this paper are available in the published
article and its additional files as well as in publically available data repositories.
The explorative mass spectrometry proteomics data have been deposited to
the ProteomeXchange Consortium via the PRIDE [126] partner repository with
the dataset identifier PXD012851 (http://proteomecentral.proteomexchange.
org/cgi/GetDataset?ID=PXD012851). Quantitative data have received the
dataset identifier PXD013451 (http://proteomecentral.proteomexchange.org/
cgi/GetDataset?ID=PXD013451) and been made available at Panorama Public
[127] (https://panoramaweb.org/PRM-MS_EndoLys_ADPD.url).
Ethics approval and consent to participate
All the procedures of the present article were performed following the




HZ and KB are co-founders of Brain Biomarker Solutions in Gothenburg AB, a
GU Ventures-based platform company at the University of Gothenburg. HZ has
served at advisory boards of Roche Diagnostics and Eli Lilly. KB has served as a
consultant or at advisory boards for Alzheon, Eli Lilly, Fujirebio Europe, IBL
International, and Roche Diagnostics. OH has acquired research support (for the
institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals,
Fujirebio, and Euroimmun. In the past 2 years, OH has received consultancy/
speaker fees (paid to the institution) from Lilly, Roche, and Fujirebio. LP has
received research reagents from Fujirebio and Euroimmun. LP has also served
as Member of Advisory Boards for Fujirebio, IBL, Roche, and Merck. The other
authors declare that they have no competing interests.
Author details
1Department of Psychiatry and Neurochemistry, Institute of Neuroscience
and Physiology, the Sahlgrenska Academy at the University of Gothenburg,
House V3, SU/Mölndal, SE-43180 Mölndal, Sweden. 2Clinical Neurochemistry
Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. 3Laboratory of
Clinical Neurochemistry, Neurology Clinic, University of Perugia, Perugia, Italy.
4Department of Experimental Medicine, University of Perugia, Perugia, Italy.
5Laboratory of Clinical Neurochemistry, Department of Medicine, University
of Perugia, Perugia, Italy. 6Clinical Memory Research Unit, Department of
Clinical Sciences Malmö, Lund University, Lund, Sweden. 7Memory Clinic,
Skåne University Hospital, Malmö, Sweden. 8Department of Molecular
Neuroscience, University College London Institute of Neurology, Queen
Square, London, UK. 9UK Dementia Research Institute at UCL, London, UK.
Received: 20 June 2019 Accepted: 22 August 2019
References
1. Alzheimer’s Association. 2017 Alzheimer’s disease facts and figures.
Alzheimers Dement. 2017;13(4):325–73.
2. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896–912.
3. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther
K. Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Proc Natl Acad Sci U S A. 1985;82(12):4245–9.
4. Wood JG, Mirra SS, Pollock NJ, Binder LI. Neurofibrillary tangles of Alzheimer
disease share antigenic determinants with the axonal microtubule-
associated protein tau (tau). Proc Natl Acad Sci U S A. 1986;83(11):4040–3.
5. Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is
a major antigenic component of paired helical filaments in Alzheimer
disease. Proc Natl Acad Sci U S A. 1986;83(11):4044–8.
6. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI.
Abnormal phosphorylation of the microtubule-associated protein tau (tau)
in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83(13):
4913–7.
7. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M.
Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839–40.
8. Dehay B, Martinez-Vicente M, Caldwell GA, Caldwell KA, Yue Z, Cookson MR, et al.
Lysosomal impairment in Parkinson's disease. Mov Disord. 2013;28(6):725–32.
9. Whyte LS, Lau AA, Hemsley KM, Hopwood JJ, Sargeant TJ. Endo-lysosomal
and autophagic dysfunction: a driving factor in Alzheimer’s disease? J
Neurochem. 2017;140(5):703–17.
10. Huotari J, Helenius A. Endosome maturation. EMBO J. 2011;30(17):3481–500.
11. Yamamoto A, Yue Z. Autophagy and its normal and pathogenic states in
the brain. Annu Rev Neurosci. 2014;37:55–78.
12. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;
67:425–79.
13. Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA.
Endocytic pathway abnormalities precede amyloid β deposition in sporadic
Alzheimer’s disease and Down syndrome. Am J Pathol. 2000;157(1):277–86.
14. Cataldo AM, Barnett JL, Pieroni C, Nixon RA. Increased neuronal endocytosis
and protease delivery to early endosomes in sporadic Alzheimer's disease:
neuropathologic evidence for a mechanism of increased beta-
amyloidogenesis. J Neurosci. 1997;17(16):6142–51.
15. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, et al. Extensive
involvement of autophagy in Alzheimer disease: an immuno-electron
microscopy study. J Neuropathol Exp Neurol. 2005;64(2):113–22.
16. Anglade P. Apoptosis and autophagy in nigral neurons of patients with
Parkinson’s disease. Histol Histopathol. 1997;12(1):25–31.
17. Dehay B, Bove J, Rodriguez-Muela N, Perier C, Recasens A, Boya P, et al.
Pathogenic lysosomal depletion in Parkinson’s disease. J Neurosci. 2010;
30(37):12535–44.
18. Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, Caballero C, Ferrer I, Obeso
JA, et al. Chaperone-mediated autophagy markers in Parkinson disease
brains. Arch Neurol. 2010;67(12):1464–72.
19. Murphy KE, Gysbers AM, Abbott SK, Spiro AS, Furuta A, Cooper A, et al.
Lysosomal-associated membrane protein 2 isoforms are differentially
affected in early Parkinson's disease. Mov Disord. 2015;30(12):1639–47.
20. Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH. Alterations in
lysosomal and proteasomal markers in Parkinson's disease: relationship to
alpha-synuclein inclusions. Neurobiol Dis. 2009;35(3):385–98.
21. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the
glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl
J Med. 2004;351(19):1972–7.
22. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al.
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.
N Engl J Med. 2009;361(17):1651–61.
Sjödin et al. Alzheimer's Research & Therapy           (2019) 11:82 Page 13 of 16
23. Sidransky E. Gaucher disease: complexity in a “simple” disorder. Mol Genet
Metab. 2004;83(1):6–15.
24. Robak LA, Jansen IE, van Rooij J, Uitterlinden AG, Kraaij R, Jankovic J, et al.
Excessive burden of lysosomal storage disorder gene variants in Parkinson’s
disease. Brain. 2017;140:3191–203.
25. Gao S, Casey AE, Sargeant TJ, Mäkinen V-P. Genetic variation within
endolysosomal system is associated with late-onset Alzheimer’s disease.
Brain. 2018;141:2711–20.
26. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al.
Genome-wide association study identifies variants at CLU and PICALM
associated with Alzheimer's disease. Nat Genet. 2009;41(10):1088–93.
27. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and
plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131–44.
28. Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. CSF
and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic
review and meta-analysis. Lancet Neurol. 2016;15(7):673–84.
29. Armstrong A, Mattsson N, Appelqvist H, Janefjord C, Sandin L, Agholme L,
et al. Lysosomal network proteins as potential novel CSF biomarkers for
Alzheimer's disease. NeuroMolecular Med. 2014;16(1):150–60.
30. Heywood WE, Galimberti D, Bliss E, Sirka E, Paterson RW, Magdalinou NK, et
al. Identification of novel CSF biomarkers for neurodegeneration and their
validation by a high-throughput multiplexed targeted proteomic assay. Mol
Neurodegener. 2015;10:64.
31. Sjödin S, Öhrfelt A, Brinkmalm G, Zetterberg H, Blennow K, Brinkmalm A.
Targeting LAMP2 in human cerebrospinal fluid with a combination of
immunopurification and high resolution parallel reaction monitoring mass
spectrometry. Clin Proteomics. 2016;13(1):4.
32. Wang GP, Iqbal K, Bucht G, Winblad B, Wisniewski HM, Grundke-Iqbal I.
Alzheimer’s disease: paired helical filament immunoreactivity in
cerebrospinal fluid. Acta Neuropathol. 1991;82(1):6–12.
33. Blennow K, Davidsson P, Wallin A, Gottfries CG, Svennerholm L. Ubiquitin in
cerebrospinal fluid in Alzheimer’s disease and vascular dementia. Int
Psychogeriatr. 1994;6(1):13–22.
34. Oeckl P, Steinacker P, von Arnim CA, Straub S, Nagl M, Feneberg E, et al.
Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple
reaction monitoring reveals differences in Alzheimer's disease and
frontotemporal lobar degeneration. J Proteome Res. 2014;13(11):4518–25.
35. Sjödin S, Hansson O, Öhrfelt A, Brinkmalm G, Zetterberg H, Brinkmalm A, et
al. Mass spectrometric analysis of cerebrospinal fluid ubiquitin in Alzheimer's
disease and parkinsonian disorders. Proteomics Clin Appl. 2017;11(11–12):
1700100.
36. Parnetti L, Cicognola C, Eusebi P, Chiasserini D. Value of cerebrospinal fluid
alpha-synuclein species as biomarker in Parkinson’s diagnosis and prognosis.
Biomark Med. 2016;10(1):35–49.
37. Balducci C, Pierguidi L, Persichetti E, Parnetti L, Sbaragli M, Tassi C, et al.
Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson’s
disease. Mov Disord. 2007;22(10):1481–4.
38. Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM, et
al. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's
disease. Mov Disord. 2014;29(8):1019–27.
39. Parnetti L, Paciotti S, Eusebi P, Dardis A, Zampieri S, Chiasserini D, et al.
Cerebrospinal fluid β-glucocerebrosidase activity is reduced in
parkinson&apos;s disease patients. Mov Disord. 2017;32(10):1423–31.
40. Boman A, Svensson S, Boxer A, Rojas JC, Seeley WW, Karydas A, et al.
Distinct lysosomal network protein profiles in parkinsonian syndrome
cerebrospinal fluid. J Park Dis. 2016;6(2):307–15.
41. Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K,
et al. A panel of nine cerebrospinal fluid biomarkers may identify patients
with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015;
86(11):1240–7.
42. Hall S, Ohrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, et al.
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential
diagnosis of patients with dementia and/or parkinsonian disorders. Arch
Neurol. 2012;69(11):1445–52.
43. Brinkmalm G, Sjödin S, Simonsen AH, Hasselbalch SG, Zetterberg H,
Brinkmalm A, et al. A parallel reaction monitoring mass spectrometric
method for analysis of potential CSF biomarkers for Alzheimer's disease.
Proteomics Clin Appl. 2018;12(1):1700131.
44. Peterson AC, Russell JD, Bailey DJ, Westphall MS, Coon JJ. Parallel reaction
monitoring for high resolution and high mass accuracy quantitative,
targeted proteomics. Mol Cell Proteomics. 2012;11(11):1475–88.
45. Gallien S, Duriez E, Demeure K, Domon B. Selectivity of LC-MS/MS analysis:
implication for proteomics experiments. J Proteome. 2013;81:148–58.
46. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al.
Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2
criteria. Lancet Neurol. 2014;13(6):614–29.
47. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The
diagnosis of mild cognitive impairment due to Alzheimer’s disease:
recommendations from the National Institute on Aging-Alzheimer’s
Association workgroups on diagnostic guidelines for Alzheimer's disease.
Alzheimers Dement. 2011;7(3):270–9.
48. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH,
et al. The diagnosis of dementia due to Alzheimer’s disease:
recommendations from the National Institute on Aging-Alzheimer’s
Association workgroups on diagnostic guidelines for Alzheimer’s disease.
Alzheimers Dement. 2011;7(3):263–9.
49. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch
Neurol. 1999;56(1):33–9.
50. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med.
2004;256(3):183–94.
51. The Swedish BIOFINDER Study. http://www.biofinder.se/. Accessed 16
Apr 2019.
52. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM.
Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work
group under the auspices of Department of Health and Human Services
Task Force on Alzheimer's disease. Neurology. 1984;34(7):939–44.
53. Hall S, Surova Y, Öhrfelt A, Blennow K, Zetterberg H, Hansson O.
Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson’s
disease. Mov Disord. 2016;31(6):898–905.
54. Chiasserini D, Biscetti L, Farotti L, Eusebi P, Salvadori N, Lisetti V, et al.
Performance evaluation of an automated ELISA system for Alzheimer’s
disease detection in clinical routine. J Alzheimers Dis. 2016;54(1):55–67.
55. McMahon HT, Boucrot E. Molecular mechanism and physiological functions
of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol. 2011;12(8):517–33.
56. Muller UC, Zheng H. Physiological functions of APP family proteins. Cold
Spring Harb Perspect Med. 2012;2(2):a006288.
57. Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic
processing of APP. Cold Spring Harb Perspect Med. 2012;2(5):a006270.
58. Mayilyan KR. Complement genetics, deficiencies, and disease associations.
Protein Cell. 2012;3(7):487–96.
59. Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B, et al. Cysteine
cathepsins: from structure, function and regulation to new frontiers.
Biochim Biophys Acta. 2012;1824(1):68–88.
60. Zaidi N, Maurer A, Nieke S, Kalbacher H. Cathepsin D: A cellular roadmap.
Biochem Biophys Res Commun. 2008;376(1):5–9.
61. Maes M-B, Scharpé S, De Meester I. Dipeptidyl peptidase II (DPPII), a review.
Clin Chim Acta. 2007;380(1):31–49.
62. Kolter T, Sandhoff K. Lysosomal degradation of membrane lipids. FEBS Lett.
2010;584(9):1700–12.
63. Lemieux MJ, Mark BL, Cherney MM, Withers SG, Mahuran DJ, James MNG.
Crystallographic structure of human β-Hexosaminidase a: interpretation of
Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis. J Mol Biol.
2006;359(4):913–29.
64. Huynh KK, Eskelinen EL, Scott CC, Malevanets A, Saftig P, Grinstein S. LAMP
proteins are required for fusion of lysosomes with phagosomes. EMBO J.
2007;26(2):313–24.
65. Saftig P, Klumperman J. Lysosome biogenesis and lysosomal membrane
proteins: trafficking meets function. Nat Rev Mol Cell Biol. 2009;10(9):623–35.
66. Ganz T. Antimicrobial polypeptides. J Leukoc Biol. 2004;75(1):34–8.
67. Johnson SW, Alhadeff JA. Mammalian α-l-fucosidases. Comp Biochem
Physiol B. 1991;99(3):479–88.
68. Gherasim C, Lofgren M, Banerjee R. Navigating the B (12) road: assimilation,
delivery, and disorders of cobalamin. J Biol Chem. 2013;288(19):13186–93.
69. Tomkinson B. Tripeptidyl peptidases: enzymes that count. Trends Biochem
Sci. 1999;24(9):355–9.
70. Komander D, Rape M. The ubiquitin code. Annu Rev Biochem. 2012;81:203–29.
71. de Graaf EL, Altelaar AF, van Breukelen B, Mohammed S, Heck AJ. Improving
SRM assay development: a global comparison between triple quadrupole,
ion trap, and higher energy CID peptide fragmentation spectra. J Proteome
Res. 2011;10(9):4334–41.
72. International Organization for Standardization. Accuracy (trueness and precision)
of measurement methods and results— Part 2: Basic method for the
Sjödin et al. Alzheimer's Research & Therapy           (2019) 11:82 Page 14 of 16
determination of repeatability and reproducibility of a standard measurement
method (Standard 5725-2:1994). International Organization for Standardization;
1994. Retrieved from https://www.iso.org/standard/11834.html.
73. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B,
et al. Skyline: an open source document editor for creating and analyzing
targeted proteomics experiments. Bioinformatics. 2010;26(7):966–8.
74. Duits FH, Brinkmalm G, Teunissen CE, Brinkmalm A, Scheltens P, Van
der Flier WM, et al. Synaptic proteins in CSF as potential novel
biomarkers for prognosis in prodromal Alzheimer’s disease. Alzheimers
Res Ther. 2018;10(1):5.
75. Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, et al.
Glucocerebrosidase deficiency in substantia nigra of parkinson disease
brains. Ann Neurol. 2012;72(3):455–63.
76. Chiasserini D, Paciotti S, Eusebi P, Persichetti E, Tasegian A, Kurzawa-
Akanbi M, et al. Selective loss of glucocerebrosidase activity in sporadic
Parkinson’s disease and dementia with Lewy bodies. Mol Neurodegener.
2015;10:15.
77. van Dijk KD, Persichetti E, Chiasserini D, Eusebi P, Beccari T, Calabresi P, et al.
Changes in endolysosomal enzyme activities in cerebrospinal fluid of
patients with Parkinson's disease. Mov Disord. 2013;28(6):747–54.
78. Parnetti L, Balducci C, Pierguidi L, De Carlo C, Peducci M, D'Amore C, et al.
Cerebrospinal fluid β-glucocerebrosidase activity is reduced in dementia
with Lewy bodies. Neurobiol Dis. 2009;34(3):484–6.
79. Gough NR, Hatem CL, Fambrough DM. The family of LAMP-2 proteins arises
by alternative splicing from a single gene: characterization of the avian
LAMP-2 gene and identification of mammalian homologs of LAMP-2b and
LAMP-2c. DNA Cell Biol. 1995;14(10):863–7.
80. Kaushik S, Cuervo AM. Chaperone-mediated autophagy: a unique way to
enter the lysosome world. Trends Cell Biol. 2012;22(8):407–17.
81. Cuervo AM, Dice JF. A receptor for the selective uptake and degradation of
proteins by lysosomes. Science. 1996;273(5274):501–3.
82. Cuervo AM, Dice JF. Age-related decline in chaperone-mediated autophagy.
J Biol Chem. 2000;275(40):31505–13.
83. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired
degradation of mutant alpha-synuclein by chaperone-mediated autophagy.
Science. 2004;305(5688):1292–5.
84. Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type alpha-synuclein is
degraded by chaperone-mediated autophagy and macroautophagy in
neuronal cells. J Biol Chem. 2008;283(35):23542–56.
85. Constantinescu R, Andreasson U, Li S, Podust VN, Mattsson N, Anckarsäter R,
et al. Proteomic profiling of cerebrospinal fluid in parkinsonian disorders.
Parkinsonism Relat Disord. 2010;16(8):545–9.
86. Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, Ihara Y. Lewy bodies are
ubiquitinated - a light and electron microscopic immunocytochemical
study. Acta Neuropathol. 1988;75(4):345–53.
87. Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VM, et
al. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy
lesions. J Biol Chem. 2002;277(50):49071–6.
88. Zhao H, Ruberu K, Li H, Garner B. Perturbation of neuronal cobalamin
transport by lysosomal enzyme inhibition. Biosci Rep. 2014;34(1):e00092.
89. Webster S, Lue LF, Brachova L, Tenner AJ, McGeer PL, Terai K, et al.
Molecular and cellular characterization of the membrane attack complex,
C5b-9, in Alzheimer’s disease. Neurobiol Aging. 1997;18(4):415–21.
90. Shen Y, Li R, McGeer EG, McGeer PL. Neuronal expression of mRNAs for
complement proteins of the classical pathway in Alzheimer brain. Brain Res.
1997;769(2):391–5.
91. Cataldo AM, Hamilton DJ, Nixon RA. Lysosomal abnormalities in
degenerating neurons link neuronal compromise to senile plaque
development in Alzheimer disease. Brain Res. 1994;640(1–2):68–80.
92. Cataldo AM, Barnett JL, Berman SA, Li J, Quarless S, Bursztajn S, et al. Gene
expression and cellular content of cathepsin D in Alzheimer’s disease brain:
evidence for early up-regulation of the endosomal-lysosomal system.
Neuron. 1995;14(3):671–80.
93. Ginsberg SD, Alldred MJ, Counts SE, Cataldo AM, Neve RL, Jiang Y, et al.
Microarray analysis of hippocampal CA1 neurons implicates early
endosomal dysfunction during Alzheimer's disease progression. Biol
Psychiatry. 2010;68(10):885–93.
94. Ginsberg SD, Mufson EJ, Alldred MJ, Counts SE, Wuu J, Nixon RA, et al.
Upregulation of select Rab GTPases in cholinergic basal forebrain neurons
in mild cognitive impairment and Alzheimer's disease. J Chem Neuroanat.
2011;42(2):102–10.
95. Musunuri S, Wetterhall M, Ingelsson M, Lannfelt L, Artemenko K, Bergquist J,
et al. Quantification of the brain proteome in Alzheimer’s disease using
multiplexed mass spectrometry. J Proteome Res. 2014;13(4):2056–68.
96. Cataldo AM, Nixon RA. Enzymatically active lysosomal proteases are
associated with amyloid deposits in Alzheimer brain. Proc Natl Acad Sci U S
A. 1990;87(10):3861–5.
97. Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V,
Larsson A, et al. Higher cathepsin B levels in plasma in Alzheimer’s disease
compared to healthy controls. J Alzheimers Dis. 2010;22(4):1223–30.
98. Manaka H, Kato T, Kurita K, Katagiri T, Shikama Y, Kujirai K, et al. Marked
increase in cerebrospinal fluid ubiquitin in Creutzfeldt-Jakob disease.
Neurosci Lett. 1992;139(1):47–9.
99. Steinacker P, Rist W, Swiatek-de-Lange M, Lehnert S, Jesse S, Pabst A, et al.
Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt-Jakob
disease. Proteomics. 2010;10(1):81–9.
100. Simonsen AH, McGuire J, Hansson O, Zetterberg H, Podust VN, Davies HA,
et al. Novel panel of cerebrospinal fluid biomarkers for the prediction of
progression to Alzheimer dementia in patients with mild cognitive
impairment. Arch Neurol. 2007;64(3):366–70.
101. Hagihara M, Mihara R, Togari A, Nagatsu T. Dipeptidyl-aminopeptidase II in
human cerebrospinal fluid: changes in patients with Parkinson’s disease.
Biochem Med Metab Biol. 1987;37(3):360–5.
102. Mantle D, Falkous G, Ishiura S, Perry RH, Perry EK. Comparison of cathepsin
protease activities in brain tissue from normal cases and cases with
Alzheimer’s disease, Lewy body dementia, Parkinson's disease and
Huntington’s disease. J Neurol Sci. 1995;131(1):65–70.
103. Helmfors L, Boman A, Civitelli L, Nath S, Sandin L, Janefjord C, et al.
Protective properties of lysozyme on β-amyloid pathology: implications for
Alzheimer disease. Neurobiol Dis. 2015;83:122–33.
104. Sandin L, Bergkvist L, Nath S, Kielkopf C, Janefjord C, Helmfors L, et al.
Beneficial effects of increased lysozyme levels in Alzheimer’s disease
modelled in Drosophila melanogaster. FEBS J. 2016;283(19):3508–22.
105. Cragg H, Williamson M, Young E, O'Brien J, Alhadeff J, Fang-Kircher S, et al.
Fucosidosis: genetic and biochemical analysis of eight cases. J Med Genet.
1997;34(2):105–10.
106. Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease:
risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106–18.
107. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small
GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of
Alzheimer’s disease in late onset families. Science. 1993;261(5123):921–3.
108. He X, Cooley K, Chung CHY, Dashti N, Tang J. Apolipoprotein receptor 2
and X11α/β mediate apolipoprotein E-induced endocytosis of amyloid-β
precursor protein and β-secretase, leading to amyloid-β production. J
Neurosci. 2007;27(15):4052–60.
109. Ji Z-S, Miranda RD, Newhouse YM, Weisgraber KH, Huang Y, Mahley RW.
Apolipoprotein E4 potentiates amyloid β peptide-induced lysosomal
leakage and apoptosis in neuronal cells. J Biol Chem. 2002;277(24):21821–8.
110. Hansson KT, Skillbäck T, Pernevik E, Kern S, Portelius E, Höglund K, et al.
Expanding the cerebrospinal fluid endopeptidome. Proteomics. 2017;
17(5):1600384.
111. Mori H, Kondo J, Ihara Y. Ubiquitin is a component of paired helical
filaments in Alzheimer's disease. Science. 1987;235(4796):1641–4.
112. Perry G, Friedman R, Shaw G, Chau V. Ubiquitin is detected in neurofibrillary
tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl
Acad Sci U S A. 1987;84(9):3033–6.
113. Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, et al. CSF
phosphorylated tau protein correlates with neocortical neurofibrillary
pathology in Alzheimer’s disease. Brain. 2006;129(Pt 11):3035–41.
114. Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C,
Davidsson P, et al. Cerebrospinal fluid markers for Alzheimer’s disease
evaluated after acute ischemic stroke. J Alzheimers Dis. 2000;2(3–4):199–206.
115. Rodríguez A, Webster P, Ortego J, Andrews NW. Lysosomes behave as Ca2+-
regulated Exocytic vesicles in fibroblasts and epithelial cells. J Cell Biol. 1997;
137(1):93–104.
116. Street JM, Barran PE, Mackay CL, Weidt S, Balmforth C, Walsh TS, et al.
Identification and proteomic profiling of exosomes in human cerebrospinal
fluid. J Transl Med. 2012;10(1):5.
117. Reddy A, Caler EV, Andrews NW. Plasma membrane repair is mediated by
Ca2+−regulated exocytosis of lysosomes. Cell. 2001;106(2):157–69.
118. Chen G, Zhang Z, Wei Z, Cheng Q, Li X, Li W, et al. Lysosomal exocytosis in
Schwann cells contributes to axon remyelination. Glia. 2012;60(2):295–305.
Sjödin et al. Alzheimer's Research & Therapy           (2019) 11:82 Page 15 of 16
119. Arantes RME, Andrews NW. A role for Synaptotagmin VII-regulated
exocytosis of lysosomes in neurite outgrowth from primary sympathetic
neurons. J Neurosci. 2006;26(17):4630–7.
120. Schutzer SE, Liu T, Natelson BH, Angel TE, Schepmoes AA, Purvine SO, et al.
Establishing the Proteome of Normal Human Cerebrospinal Fluid. PLoS One.
2010;5(6):e10980.
121. Guldbrandsen A, Vethe H, Farag Y, Oveland E, Garberg H, Berle M, et al. In-
depth characterization of the cerebrospinal fluid (CSF) proteome displayed
through the CSF proteome resource (CSF-PR). Mol Cell Proteomics. 2014;
13(11):3152–63.
122. Hladky SB, Barrand MA. Mechanisms of fluid movement into, through
and out of the brain: Evaluation of the evidence. Fluids Barriers CNS.
2014;11(1):26.
123. Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E,
et al. Clearance systems in the brain-implications for Alzheimer disease. Nat
Rev Neurol. 2015;11(8):457–70.
124. Chiasserini D, van Weering JRT, Piersma SR, Pham TV, Malekzadeh A,
Teunissen CE, et al. Proteomic analysis of cerebrospinal fluid
extracellular vesicles: A comprehensive dataset. J Proteomics. 2014;
106(Supplement C):191–204.
125. Goetzl EJ, Boxer A, Schwartz JB, Abner EL, Petersen RC, Miller BL, et al.
Altered lysosomal proteins in neural-derived plasma exosomes in preclinical
Alzheimer disease. Neurology. 2015;85(1):40–7.
126. Vizcaíno JA, Côté RG, Csordas A, Dianes JA, Fabregat A, Foster JM, et al. The
proteomics identifications (PRIDE) database and associated tools: status in
2013. Nucleic Acids Res. 2012;41(D1):D1063–D9.
127. Sharma V, Eckels J, Schilling B, Ludwig C, Jaffe JD, MacCoss MJ, et al.
Panorama public: a public repository for quantitative data sets processed in
skyline. Mol Cell Proteomics. 2018;17(6):1239–44.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Sjödin et al. Alzheimer's Research & Therapy           (2019) 11:82 Page 16 of 16
